GOSS

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational drug products for rare diseases. Its primary product, seralutinib, is an inhaled inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company conducts clinical research, including the PROSERA Study, to advance its therapies and improve patient outcomes.